This post was contributed by Etta Pisano, MD, FACR, principal investigator of the Tomosynthesis Mammographic Imaging Screening Trial (TMIST).
Criticisms of some large clinical trials include that the research was confined to large academic centers and that patient populations lacked sufficient representation from underserved communities.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is taking steps to avoid such pitfalls. I recently explained to ACR-RBMA Practice Leaders Forum attendees how their practice or department can benefit by take part in TMIST. The response was fantastic!
It appears many freestanding or outpatient imaging facility leaders have rarely been approached to take part in a large study. That is a shame.
While we thank — and are proud of — all the large institutions taking part in TMIST (and we want more to take part), we are also seeking a mix of facility types to demonstrate that trial results are applicable across care settings.
TMIST participation can also empower your practice to offer the latest care to underserved populations and expand minority and rural resident participation in clinical trials.
Sites receive $500 for the recruitment of each woman to the study and the submission of the data on the first round of screening, plus $150 for data submitted after each additional TMIST-required screening mammogram.
What makes TMIST different from most other federally funded trials is that for uninsured women recruited to the study who qualify for charity care at a participating facility, the site also receives $138 for each TMIST screening mammogram (on top of the $500 and $150 mentioned above).
This is a new and rare opportunity — one that I am proud to say TMIST can offer to practices.
TMIST seeks to identify groups of women in which tomosynthesis may outpace digital mammography at reducing advanced cancer development. TMIST would also create the world’s largest bio-repository to tailor future risk-based screening policy.
I encourage you to get involved in shaping the future of breast cancer screening by participating in TMIST. Decision makers rarely update policy without such a randomized, controlled trial.
Now is the time to get involved.
Email TMIST@acr.org — we will answer your questions and walk you through how to get started.
Please provide your thoughts in the comments section below and join the discussion on Engage (login required).